Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lol. So many conspiracies! Yeah, a story about a former Bush public servant, ex Enron executive trying to finish up her career by curing cancer...except for Israel and a nasty billionaire standing in her way. That wouldn't make a great news story. Lol.
Just like when Peregrine's cancer trial was alleged to have been sabotaged by one women and some players in the background. Nobody was interested in getting that one out either. Even the shareholders never really got a straight answer.
These stories are all just created to consume retail in some crazy soap opera. A hook to take your money.
It's called branding. 60 Minutes....Of course they can.
Feuerstein is one of the very few addressing snake oil salesman in biotech. He's much appreciated by any investor with common sense.
What a great story for 60 Minutes. I wonder how many times Powers and Les have submitted their story to get the outraged public behind them? Oh wait, think I know how many - ZERO! Lol.
He was working to get on Trump's team and probably is still. Face it...The guy was a no show. Powers likely used his impressive credentials to pacify shareholders just long enough to get to this point...broke and broken.
You really still believe Black or anyone else is on the trail? The company is on the verge of going under and the board has destroyed shareholders with their silence. Most are gone already.
Then Woodford could get to the bottom of it but, sadly, it appears he has no appetite. He trashed a hundred million plus while seriously letting down his followers and fellow shareholders, and all for what? He should want and need to get to the bottom of it.
I think that's right and therefor OS wasn't even on the radar.
I love your reply in the form of a daily affirmation. Remarkable you can see light at the end of this tunnel. Here's to the human spirit! Lol.
On another note, I've watched Rodman operate for probably twenty five years. Not a good record for shareholders, imo.
"The end is all that matters not the journey"
End for who...Management or Shareholders? Because most shareholders have already been carried out in body bags and with no ceremony, I might add. Your statement is a punch in the face to loyal shareholders and why i find it so difficult to believe you people here.
Now why would that be? Good news on either would ruin shorts. Likely OS isn't even being discussed behind closed doors. They may have accidentally just told us something??
It was Opie and this board is Mayberry.
Yes Powers is the Grand Master of chess. Lol.
And don't forget all the angry wives. Lol.
It's Rodman so bear case.
This does not feel legal in any way.
Nobody cares about this. All good. Buy more. Lol.
Sometimes you don't get what you want, you get what you need!
Nice. Quadruple down! Great strategy. Lol.
Incorrect. That paragraph was pulled from S14 in the Supplement section.
Under this shelf registration process, we are offering to sell Common Stock, Warrants, and shares of Common Stock issuable upon exercise of the Warrants using this prospectus supplement and the accompanying prospectus. In this prospectus supplement, we provide you with specific information about the securities that we are selling in this offering. Both this prospectus supplement and the accompanying prospectus include important information about us, our securities being offered and other information you should know before investing. This prospectus supplement also adds, updates and changes information contained in the accompanying prospectus. You should read this prospectus supplement and the accompanying prospectus as well as additional information described under “Incorporation of Certain Documents by Reference” on page S-23 of this prospectus supplement before investing in our securities.
This prospectus supplement describes the specific terms of an offering of our securities and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into the accompanying prospectus. The second part, the accompanying prospectus, provides more general information. If the information in this prospectus supplement is inconsistent with the accompanying prospectus or any document incorporated by reference therein filed prior to the date of this prospectus supplement, you should rely on the information in this prospectus supplement.
Why is this "partial clinical hold" in the latest filing?
Multiple late stage clinical trials of DCVax-L for GBM, our lead product, may be required before we can obtain regulatory approval.
Typically, companies conduct multiple late stage clinical trials of their product candidates before seeking product approval. Our current Phase III 331-patient clinical trial of DCVax-L for GBM is our first late stage trial. We may be required to conduct additional late stage trials with DCVax-L for GBM before we can obtain product approval. This would substantially delay our commercialization. In addition, our Phase III trial of DCVax-L is on a partial clinical hold for new screening for enrollment. We do not know what will happen with this partial hold. Although we have over 300 of the planned 331 patients already enrolled in this trial, and they have continued to be treated without interruption, we may not be released from the screening hold and may not be able to complete the planned enrollment in this trial. There is also some possibility that changes requested by the FDA and/or other regulators could complicate the application process for product approval. In addition, a rapidly growing number of products are under development for brain cancer, including immunotherapies such as checkpoint inhibitor drugs and T cell based therapies, and some (e.g., NovoCure’s device) have been approved in the U.S. It is possible that the standard of care for brain cancer could change while our Phase III trial is still under way. This could necessitate further clinical trials with our DCVax-L product candidate for brain cancer.
Yep, no comment. Boiler room behind shut door trying to get the story straight on this one. Good luck. Lol.
Meirluc wants to make sure my last post gets off page one.
His last filing was three months ago so who knows. Plus he's probably pawned it off or at least hedged it by now.
I thought the company said the FDA dismissed the hold? This from the latest filing:
Multiple late stage clinical trials of DCVax-L for GBM, our lead product, may be required before we can obtain regulatory approval.
Typically, companies conduct multiple late stage clinical trials of their product candidates before seeking product approval. Our current Phase III 331-patient clinical trial of DCVax-L for GBM is our first late stage trial. We may be required to conduct additional late stage trials with DCVax-L for GBM before we can obtain product approval. This would substantially delay our commercialization. In addition, our Phase III trial of DCVax-L is on a partial clinical hold for new screening for enrollment. We do not know what will happen with this partial hold. Although we have over 300 of the planned 331 patients already enrolled in this trial, and they have continued to be treated without interruption, we may not be released from the screening hold and may not be able to complete the planned enrollment in this trial. There is also some possibility that changes requested by the FDA and/or other regulators could complicate the application process for product approval. In addition, a rapidly growing number of products are under development for brain cancer, including immunotherapies such as checkpoint inhibitor drugs and T cell based therapies, and some (e.g., NovoCure’s device) have been approved in the U.S. It is possible that the standard of care for brain cancer could change while our Phase III trial is still under way. This could necessitate further clinical trials with our DCVax-L product candidate for brain cancer.
Lol. And then add to it the Phase Five charge that went without any formal investigation update.
Many daily affirmations there. You don't even really know if Woodford is still in the game.
Well, if you consider "somewhere" a quick fifty percent move up from 15 cents then a slow fallback, stick around, I guess.
It's even worse; Suppose the company somehow manages to announce some top line efficacy, if nobody believes in the trial anymore or the ability to commercialize it wont matter. Then consider what Peregrine did to the investment community with its retracted top line. Add to that whatever Woodford is still holding, he'll likely be selling all the way. I'd bet the stock goes nowhere on such an announcement.
"Ability to tolerate ongoing risk"
You just refuse to get it...Your investment was turned to sawdust, compliments of Ms Powers, so whatever it is you think you're tolerating is over!
In truth anyone who invested in this governance-less stock has lost nearly everything. If you want to believe pros wouldn't step in when the the stock is down ten, twenty, thirty percent, that's possible. But fifty, sixty, seventy, eighty percent off and nobody steps in, than why even bother with analysis at all? It's not like this stock is flying under the radar as it's been tossed around for decades.
I guess the street pros aren't following the breadcrumbs like well trained retail. LOL.
Great post! Many longs are hoping the shares hit ten cents so they can load the boat one final time. Powers plan is impressive thus far. Bring on those evil short attacks...The more merrier. Chris runs the grey edge. It's all a beautiful thing.
LOL.
Proper governance to achieve better raises and less dilution? ...shareholders?
Biden thinks DCVax stands for District of Columbia Virginia generation.
Maybe forced admission of wrong doing on NWBO CFO or Cognate President part or both? Anyway, looks like shareholders will pay for it so all is well, right guys?. Lol.
Oh, right, that too. Lol.
Because CEO is the CFO is the Chairman who once worked for Enron and a reputation with Toucan and burning other peoples cash?
...But look at the bright side, you are already as close to zero as you can get, compliments of Mrs. Powers.
A hopeful story has to be created to justify a reverse split. This one is likely a shell in waiting for a reverse merge of some new business. Warrants will likely be repriced at such time. Retail shareholders will hit near zero.
All cleaned up. All relevance neatly deleted. Shameful.